Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
Crossref DOI link: https://doi.org/10.1007/s13300-015-0128-9
Published Online: 2015-09-01
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ptaszynska, Agata
Cohen, Samuel M.
Messing, Edward M.
Reilly, Timothy P.
Johnsson, Eva
Johnsson, Kristina
Funding for this research was provided by:
AstraZeneca
Text and Data Mining valid from 2015-09-01
Article History
Received: 8 June 2015
First Online: 1 September 2015